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MaOBJECTIVES The purpose of this study was to analyze the effect of transcatheter aortic valve replacement (TAVR)
without versus with prior balloon aortic valvuloplasty (BAV) on the risk of cerebral embolization in patients who receive a
balloon-expandable valve.
BACKGROUND Avoiding BAV prior to TAVR may simplify the procedure, but the risk of cerebral embolization is
currently unknown.
METHODS A total of 87 consecutive high surgical-risk patients with no contraindications for diffusion-weighted
magnetic resonance imaging (DW-MRI) were enrolled. Thirty-two patients received a balloon-expandable aortic valve
with and 55 patients without BAV. The incidence, number, and volume of new ischemic lesions in DW-MRI performed
2 to 7 days after TAVI were evaluated.
RESULTS Mean age (83.8  5.2 years vs. 82.9  6.8 years) and sex (43.8% vs. 52.7% male) of the patients with versus
without BAV, respectively, as well as other demographic and hemodynamic data were not signiﬁcantly different between
both groups. The procedural success rate was 93.5% with and 98.2% without BAV, and procedure duration and contrast
volume were signiﬁcantly lower without BAV. The incidence of new cerebral ischemic lesions in the total cohort was
66.7%. Compared with patients with BAV, those without BAV had a signiﬁcantly higher total volume of cerebral ischemic
lesions (235.4  331.4 mm3 vs. 89.5  128.2 mm3; p ¼ 0.01).
CONCLUSIONS The implantation of a balloon-expandable aortic valve without versus with prior BAV, although
performed with a shorter procedure time and lower contrast volume, is associated with a signiﬁcantly higher volume
of cerebral ischemic lesions. (J Am Coll Cardiol Intv 2015;8:1608–13) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
BAV = balloon valvuloplasty
DW-MRI = diffusion-weighted
magnetic resonance imaging
TAVR = transcatheter aortic
valve replacement
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1609The aim of the present study was to analyze the
effect of implanting a balloon-expandable valve
without prior BAV on cerebral embolization compared
with patients who received the balloon-expandable
valve after BAV.
METHODS
Consecutive patients who met the inclusion/exclu-
sion criteria were enrolled in the present study.
Inclusion criteria were the presence of symptomatic
severe aortic stenosis, age >75 years, and a high sur-
gical risk as determined by an interdisciplinary heart
team.
Exclusion criteria were pacemaker, claustrophobia,
refusal of diffusion-weighted magnetic resonance
imaging (DW-MRI), a history of a stroke or transient
ischemic attack (TIA) within the prior 6 months,
renal failure (estimated glomerular ﬁltration rate
<30 ml/min, calculated from serum creatinine by the
Cockcroft-Gault formula), presentation with cardio-
genic shock or severe hypotension (systolic blood
pressure <90 mm Hg), undergoing any other cardiac
surgical or interventional procedure (e.g., concurrent
coronary revascularization) during or after the TAVR
procedure before DW-MRI, and experiencing a clinical
apparent stroke within 3 days after TAVR.
The patients underwent a standard screening
procedure including echocardiography and multislice
computed tomography. Aortic annulus size was
measured by multislice computed tomography and
transesophageal echocardiography (TEE) and aortic
effective oriﬁce valve area by TEE.
PROCEDURE. Patients were either on dual anti-
platelet therapy (aspirin 100 mg plus clopidogrel
75 mg/day) before TAVR or received a loading dose of
aspirin 500 mg intravenously and clopidogrel 600 mg
orally on the day of the procedure. Dual antiplatelet
therapy was recommended for 6 months. Patients on
oral anticoagulation therapy received a clopidogrel
loading dose followed by 75 mg/day for 6 months. The
TAVR procedure was performed either under general
anesthesia or conscious sedation. For BAV, a dedi-
cated Edwards SAPIEN valvuloplasty balloon catheter
(Edwards Lifesciences, Irvine, California) was used.
All patients received heparin to increase the activated
clotting time >250 s.
DIFFUSION-WEIGHTED MAGNETIC RESONANCE
IMAGING. Cerebral DW-MRI was performed 2 to 7
days after TAVR using a 1.5-T machine (Magnetom
Sonata, Siemens, Erlangen, Germany). Echo planar
imaging with the following parameters was used:
repetition time 3,000 ms; echo time 84 ms; 19 sliceswith a slice thickness of 6 mm; ﬁeld of
view 230 mm; diffusion values b ¼ 0, 500,
and 1,000 s/mm2; fat saturation; and time
of acquisition 71 s. Additionally, apparent
diffusion coefﬁcient maps were obtained. A
new lesionwas deﬁned as a focal hyperintense
area detected by the ﬂuid-attenuated inver-
sion recovery sequence, corresponding to a
restricted diffusion signal in the diffusion-weighted
imaging sequence, and conﬁrmed by apparent diffu-
sion coefﬁcient mapping to rule out a shine-through
artefact. Two independent physicians (T.H., R.G.)
analyzed the DW-MRI for new ischemic lesions. The
incidence, number, and volume of new ischemic
lesions in DW-MRI were evaluated by physicians
unaware of the patients’ treatment. Interobserver
agreement revealed a kappa of 0.75 (p < 0.001).
DEFINITIONS. According to the Valve Academic
Research Consortium-2 criteria (3), technical success
was deﬁned as successful vascular access, deploy-
ment of the device and retrieval of the delivery sys-
tem, and correct position of the device in the proper
anatomical location with adequate performance of
the prosthetic heart valve and without use of multiple
prostheses.
Major adverse cardiac and cerebrovascular events
(MACCE) were deﬁned as death, myocardial infarc-
tion, and stroke.
Stroke was deﬁned as new prolonged (>24 h) or
persistent neurological deﬁcit.
STATISTICS. Continuous data were presented as
mean  SD and compared with the unpaired t test or
Mann-Whitney U test as appropriate. Categorical data
were presented as count (percentages) and compared
with the chi-square test. A p < 0.05 was considered
statistical signiﬁcant. Interobserver variability was
evaluated by kappa statistics. Statistical analysis was
performed using GraphPad Prism version 6.0.
(GraphPad Software, San Diego, California) and SPSS
software (version 20.0, SPSS Inc., Chicago, Illinois).
RESULTS
A total of 87 patients were included in the study. In 32
patients, TAVR was performed with prior BAV, and in
55 patients, TAVR was performed without BAV. All
patients who received an Edwards SAPIEN XT valve
(n ¼ 19) routinely had BAV before valve implantation.
After the availability of the Edwards SAPIEN 3 valve,
only in case of a severe asymmetric valve calciﬁcation
or a planimetric aortic valve effective oriﬁce
area #0.5—as measured by intraprocedural TEE—was
a valvuloplasty performed (n ¼ 13). All other patients
TABLE 1 Baseline Characteristics
TAVR With BAV
(n ¼ 32)
TAVR Without BAV
(n ¼ 55) p Value
Age 83.8  5.2 82.9  6.8 0.81
Male 43.8 52.7 0.42
Logistic EuroSCORE, % 23.7  16.0 21.4  15.1 0.70
Arterial hypertension 73.3 81.8 0.27
Hyperlipoproteinemia 50.0 50.9 0.80
Diabetes mellitus 15.6 27.34 0.25
Atrial ﬁbrillation 28.1 34.5 0.70
CAD 65.6 69.1 0.93
Previous CABG 21.8 20.0 0.78
Previous stroke 15.6 16.4 0.97
COPD 9.4 12.7 0.67
Peripheral artery disease 21.8 20.0 0.75
Values are mean  SD or %.
BAV ¼ balloon aortic valvuloplasty; CABG ¼ coronary artery bypass grafting;
CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease;
TAVR ¼ transcatheter aortic valve replacement.
TABLE 2
AV mean
EOA, cm2
Annulus, m
EF, %
Values are m
AV ¼ aort
as in Table
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1610receiving an Edwards SAPIEN 3 valve were treated
without BAV (n ¼ 55).
Within 3 days following TAVR, 4 patients (3 pa-
tients without, 1 patient with BAV) experienced a
stroke and were excluded from the study.
The patient demographics are summarized in
Table 1. There were no differences between patients
with versus without BAV in terms of age, sex, and
comorbidities. Also transvalvular aortic gradient,
effective aortic oriﬁce area, aortic annulus size, as
well as left ventricular function were not statistically
different (Table 2).
The procedural results are summarized in Table 3.
The procedural success rate was 93.5% in the patients
with and 98.2% in patients without BAV driven by a
difference in moderate aortic insufﬁciency post
TAVR. The rate of paravalvular leaks was not
different between both groups. Post-dilation was
performed in 3 patients without BAV and in 1 patient
with BAV due to moderate aortic regurgitation. Pa-
tients without BAV had a signiﬁcantly shorter proce-
dure duration and contrast volume.Echocardiography Baseline
TAVR With BAV
(n ¼ 32)
TAVR Without BAV
(n ¼ 55) p Value
gradient, mm Hg 40.5  13.4 40.0  12.7 0.89
0.71  0.2 0.76  0.2 0.29
m 22.8  2.8 23.1  2.3 0.69
57.2  11.9 53.0  13.8 0.15
ean  SD.
ic valve; EF ¼ ejection fraction; EOA ¼ effective oriﬁce valve area; other abbreviations
1.The 30-day MACCE rate was 0%. Major vascular
complications according to the Valve Academic
Research Consortium-2 criteria were found in 3.4%
(n ¼ 3) of patients. All 3 patients had major access
site–related bleeding requiring surgical intervention.
Nine patients (10.3%) needed a covered stent im-
plantation due to access site–related perforation or
dissection. There were no differences in vascular
complications between the 2 groups.
DW-MRI DATA. DW-MRI was performed 4.8  2.4
days after TAVR. The timing of DW-MRI was signiﬁ-
cantly different, at 4.3  2.5 days post-intervention in
the BAV group compared with 5.1  2.4 days in pa-
tients without BAV (p ¼ 0.03).
The results of the cerebral DW-MRI are summa-
rized in Figure 1.
The incidence of new ischemic cerebral lesions in
the total cohort was 66.7% (n ¼ 58). In patients
with lesions, they were located bilaterally in 43.1%
(n ¼ 25), in the right hemisphere in 24.1% (n ¼ 14) and
in the left hemisphere in 32.8% (n ¼ 19). Compared
with patients with BAV, those without BAV had a
signiﬁcantly higher total volume of cerebral ischemic
lesions and a numerically higher incidence and
number of ischemic lesions, which, however, was not
statistically signiﬁcant.
DISCUSSION
The main ﬁndings of the present study are that
implantation of a balloon-expandable valve without
prior BAV is associated with a high procedural success
rate and, compared to TAVR with BAV, with a signi-
ﬁcantly shorter procedure duration and contrast vol-
ume but with a higher cerebral embolic burden.
Balloon valvuloplasty before implantation of a
percutaneous aortic valve is widely used to facilitate
the crossing of the calciﬁed aortic valve. So far, few
studies have investigated the clinical value of avoid-
ing dilation of the stenotic valve before TAVR (2,4). In
a pilot study comprising 60 consecutive patients, who
received the self-expandable CoreValve (Medtronic,
Minneapolis, Minnesota) without pre-dilation, Grube
et al. (2) found a feasibility and safety of TAVR similar
to the standard approach with pre-dilation. Post-
dilation, however, known to be an independent risk
factor for stroke, had to be performed in 16.7% of the
patients.
Other small studies demonstrated the feasibility
of the transfemoral implantation of the Edwards
SAPIEN XT valve without prior BAV (5,6). The authors
of the previously mentioned papers speculated that
avoiding pre-dilation may reduce the risk of stroke.
FIGURE 1 Cerebral Diffusion-Weighted Magnetic Resonance Imaging Data
(A) Incidence of ischemic lesions; (B) number of ischemic lesions; and (C) volume of
ischemic lesions. BAV ¼ balloon aortic valvuloplasty.
TABLE 3 Procedural Results
TAVR With BAV
(n ¼ 32)
TAVR Without BAV
(n ¼ 55) p Value
Paravalvular regurgitation
None or trace 70.9 67.2
Mild 22.6 30.9 0.42
Moderate 6.5 1.8
Severe 0 0
Duration of procedure 69.2  41.7 58.7  31.6 0.008*
Contrast, ml 97.0  50.8 69.8  22.5 0.004*
Fluorscopy, min 15.2  8.2 14.9  9.9 0.66
Radiation dose, mGym2 3.8  1.7 5.9  6.9 0.10
Values are % or mean  SD. *p < 0.05.
Abbreviations as in Table 1.
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1611However, the effect of this strategy on the rate of ce-
rebral embolization has not been investigated so far.
Compared with the Edwards SAPIEN XT, the de-
livery system of the Edwards SAPIEN 3 aortic valve
prosthesis has a lower proﬁle and a steerable and
supportive delivery catheter, all of which may facili-
tate a direct valve implantation. We assumed that
using a less bulky TAVR device with a simpliﬁed
implantation technique (by avoiding pre-dilation)
may exert beneﬁcial effects on the periprocedural
rate of cerebral embolization.
Indeed, in the present study TAVR without BAV
compared with TAVR with BAV was feasible and led
to a signiﬁcantly shorter procedure duration and
contrast volume. This is consistent with data from
Möllmann et al. (5), who in a retrospective study,
found lower volume of contrast dye and a trend for a
shorter procedure duration in 26 patients receiving an
Edwards SAPIEN XT valve without versus 30 patients
with pre-dilation.
The MACCE rate in the present study was 0%,
without any death, stroke, or myocardial infarction
at 30 days. This excellent result may in part be
explained by the exclusion of patients in unstable
condition from the study according to the inclusion/
exclusion criteria. Of note, however, there was no
difference in the rate of stroke between patients with
compared with patients without pre-dilation, who
could not be included in the study.
TAVR AND CEREBRAL ISCHEMIC LESIONS. DW-MRI
allows detection and localization of cerebral ischemic
lesions which are found in 74% to 100% of patients
after TAVR (7–9). Patients with ischemic lesions have
a 3-fold risk of stroke (10). Although in most in-
stances, these lesions are not associated with
apparent neurological symptoms, there is a growing
body of evidence linking silent ischemic lesions to
dementia and decline in cognitive function (11,12).
Whereas those associations have been found after
CABG (13) or left heart catheterization (14), few
studies have investigated their clinical signiﬁcance in
the context of TAVR.
In the randomized CLEAN-TAVI (CLaret Embolic
Protection ANd TAVI- Trial) study, the use of a cerebral
protection device in patients undergoing TAVR
signiﬁcantly reduced the number of DW-MRI cerebral
ischemic lesions, which was associated with improved
short-term neurological outcome (15). The results of
the recently published randomized DEFLECT III
(A Prospective, Randomized Evaluation of the
TriGuard HDH Embolic Deﬂection Device During
TAVI) trial (16) are pointing in the same direction.
A reduction of ischemic brain volume underneuroprotection was associated with improvement in
short-term and delayed memory.
In spite of this data, the higher cerebral ischemic
burden found in patients undergoing TAVR without
pre-dilation in the present study is of concern. The
reason for this ﬁnding remains speculative.
In the present study, we had a signiﬁcant difference
in timing of DW-MRI after TAVR (0.8 day) between the
2 groups, which could affect the results. Also others
used a time range between 2 and 7 days for DW-MRI
(9,16). In the CLEAN TAVI trial (15), serial DW-MRIs
were performed at days 2 and 7, revealing a numeri-
cal decrease in the number and volume of lesions at
day 7 compared with day 2. In the PROTAVI-C pilot
study (Prospective Randomized Outcome study in
patients undergoing TAVI to Examine Cerebral
PERSPECTIVES
WHAT IS KNOWN? In the majority of patients,
mostly silent cerebral ischemic lesions are present
after TAVR. There is evidence that silent ischemic le-
sions are linked to dementia and decline in cognitive
function at long term. Omitting BAV before aortic
valve implantation may simplify the procedure and
may affect cerebral embolization.
WHAT IS NEW? Implantation of a balloon-
expandable valve without prior BAV was associated
with a signiﬁcantly shorter procedure duration and
lower contrast volume, but with a signiﬁcantly higher
volume of cerebral ischemic lesions.
WHAT IS NEXT? This ﬁnding has to be proven in a
randomized trial.
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1612Ischemia and Bleeding Complications) (9), by 30 days
after TAVR all new lesions had disappeared. Based on
these ﬁndings, later cardiac magnetic resonance im-
aging could have missed some new lesions. However,
in the present study, it was the group of patients with
a higher lesion volume (TAVRwithout BAV) which was
studied 0.8 day later; thus, a disappearance of pre-
existing lesions cannot explain the difference.
From primary stenting of coronary lesions, it is
known that pre-dilation is associated with at least a
trend for less myocardial injury (17). It can be specu-
lated that pre-dilation leads to plaque fragmentation,
which can reduce the risk of embolization and the size
of pieces that embolize during stent implantation. Our
ﬁndings are in support with this assumption. Themain
difference between the 2 groups was the volume of
ischemic brain, which was signiﬁcantly higher in pa-
tients without pre-dilation, whereas the incidence and
the number of lesions were not signiﬁcantly different.
CLINICAL IMPLICATIONS. The present study is the
ﬁrst to provide insights into the risk of cerebral
embolization when omitting BAV prior to balloon-
expandable aortic valve implantation. It remains to
be shown whether this translates into a higher stroke
rate. Even if not, cerebral ischemic lesions potentially
deteriorate neurocognitive function and should
therefore be avoided. Cerebral embolic protection
devices may be of speciﬁc value for TAVR without
BAV using a balloon-expandable valve.
STUDY LIMITATIONS. This is a single-center, non-
randomized studywith a small number of patients, and
therefore needs to be conﬁrmed in a larger randomized
patient population. Patients undergoing Edwards SA-
PIEN 3 without BAV were compared with a historical
control group of patients who received either an
Edwards SAPIEN XT or an Edwards SAPIEN 3 aortic
valve with BAV. Evenwith the use of the higher-proﬁle
and less-ﬂexible SAPIEN XT device in the group withBAV, the difference in ischemic lesion volume was
highly signiﬁcant emphasizing the role of pre-dilation
to reduce the risk of cerebral embolization.
CONCLUSIONS
The implantation of a balloon-expandable aortic
valve without prior BAV is associated with a signiﬁ-
cantly shorter procedure duration and lower contrast
volume than implantation with prior BAV. A sig-
niﬁcant higher volume of cerebral ischemic lesions
after TAVI without BAV, however, is of concern and
needs to be addressed by further studies.
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